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Background: Among the patients with bladder cancer, a group is still at riskof disease recurrence, progression,
and death from their cancer after curative treatment. Angiogenesis is a crucial pathogenic mechanism for this
type of urothelial carcinoma and is a potential therapeutic target.
Objectives: To quantify tumor angiogenesis in bladder cancer and determine whether it correlates with tumor
stage and grade.
Patients and methods: A series of 42 archival samples from carcinomas of the urinary bladder were graded,
staged, and analyzed for microvessel density (MVD) by a double immunohistochemical technique using
Factor VIII (FVIII) and CD31 antibodies. The correlation between MVD and histopathological grade and
tumor stage was evaluated.
Results: FVIII and CD31 immunoreactivity was observed in 100% of cases and more intensely with CD31.
Significantly higher MVD was determined in invasive tumors than in superficial tumors (pB0.05). MVD
increased with tumor grade and stage (pB0.05); MVD was not affected by age or sex of the patients.
Conclusion: These data demonstrate that MVD in bladder carcinoma correlates with the tumor grade and
stage. Quantification of tumor angiogenesis may allow selection of the type of treatment for bladder cancer
patients.
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A
ngiogenesis is the growth of new blood vessels,
which is an important natural process at various
anatomic sites. Angiogenesis occurs as an essen-
tial part of normal healing of wounds as well as in
restoring blood flow to the tissues after injury. In many
disease states, however, the body loses its normal control
of angiogenesis. In the case of cancer, excessive angiogen-
esis occurs when cancer cells produce abnormal amounts
of angiogenic growth factors, overwhelming the effects of
natural angiogenesis inhibitors. These new vessels allow
tumors to grow and cells to escape into the circulation
and lodge in other organs (1). Taking this into account,
potential anti-angiogenic therapies may have an impor-
tant role in the treatment procedure (2, 3).
Bladder cancer is the 5th most common malignant
disease and the 10th most common cause of cancer
deaths, with more than 67,000 new cases diagnosed
annually in the United States (4). About 382,660 cases
are estimated worldwide in 2008 accounting for 5.3% of
all cancers in both sexes (5). Like all solid tumors, it
requires an active angiogenesis to support its growth and
progression (6). Bladder tumor-associated angiogenesis is
emerging as an important prognostic factor and repre-
sents a promising potential therapeutic target for cancer
treatment (7).
CD31 is a 130 kDa integral membrane protein, also
known as PECAM-1 (Platelet Endothelial Cell Adhe-
sion Molecule-1), a member of the immunoglobulin
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is expressed constitutively on the surface of adult and
embryonic endothelial cells and is weakly expressed on
many peripheral leukocytes and platelets. It has also
been detected on bone marrow-derived hematopoietic
stem cells and embryonic stem cells. Another important
glycoprotein present in human endothelial cells is FVIII-
related antigen, also present in megakaryocytes and
platelets. Immunohistochemical staining for FVIII-re-
lated antigen could be used to determine if the benign
and malignant neoplastic lesions are of endothelial cell
origin (8).
Many researchers aimed for qualitative and quantita-
tive assessment of angiogenesis in urinary bladder
carcinoma (9), while others used the morphometric
characteristics of the tumor microvasculature as predictor
for prognosis (10). The present study was conducted to
quantify the microvessel density (MVD), identifying the
vessels by their immunohistochemical expression of
CD31 and FVIII antigens. MVD was correlated with a
variety of clinicopathological variables to get insight in
their potential prognostic and predictive value in bladder
cancer.
Materials and methods
Patients
A series of 42 Libyan patients (6 females, 36 males) with
invasive urinary bladder carcinoma were retrospectively
studied. Age of the patients ranged from 43 to 81 years
(mean 63.9 years). All carcinomas were selected from the
archives of the Department of Pathology, derived from
the period from 2007 to 2010, based on availability of
representative paraffin blocks. An experienced patholo-
gist confirmed all histological diagnoses. All tumors were
classified using the histopathological criteria of the World
Health Organization (WHO) classification, and staging
was made according to the American Joint Committee on
Cancer system. Four normal bladder samples were used
as control group. Clinical data of the patients are
presented in Table 1.
Immunohistochemical method
Paraffin-embedded blocks of the primary tumors were
cut serially at 5 mm for immunohistochemical (IHC)
staining. The IHC analysis was done using the automatic
system (Bench-Mark XT, Ventana Medical System,
Tucson, Arizona). This fully automated processing for
bar code labeled slides included baking of the slides,
solvent free deparaffinization, antigen retrieval in a cell
conditioning buffer CC1 (mild: 36 min conditioning, and
standard: 60 min conditioning), incubation with poly-
clonal FVIII antibody (clone: rabbit polyclonal, Ventana
Medical Systems, Inc. Tucson, Arizona, USA) at a
dilution 1:100/(60 min at room temperature). The same
method was followed for monoclonal CD31 antibody
(clone: AC-1A1, Ventana Medical Systems, Inc. Tucson,
Arizona, USA) at a dilution 1:50/(60 min at room
temperature). The IHC staining was visualized using
Ultra View
TM universal DAB, containing the following
reagents: ultra view universal HRP, ultra view universal
DAB inhibitor, ultra view universal DAB chromogen,
ultra view universal DAB H2O2, and ultra view universal
DAB copper. This was followed by counterstaining with
hematoxylin 2021 for 4 min, and post-counterstaining
with bluing reagent (2037) for 4 min. After staining, the
sections were dehydrated in ethanol, cleared in xylene,
and covered with Mountex and cover slips. Tonsil tissue
was used as an external positive control and four normal
urothelial samples were used as a normal reference.
Evaluation of IHC staining
The CD31 and FVIII positivity was indicated by the
presence of cytoplasmic or membranous brown staining.
Microvessel counting was performed in areas with max-
imal neovascularization within the tumors, outside any
areas of artifact, necrosis, or inflammation, and without
prior knowledge of the patient outcome. Low-power light
microscopy (at 40) magnification was used to scan the
heterogeneous tumor sections for these areas. At100
Table 1. Key characteristics of the patients and their tumors
Variable Number or value Percentage%*
Patients
Male 36 85.7
Female 6 14.3
Age (years)
Range (4381) 
Mean 63.95 
Median 65.00 
Standard deviation 9.80 
Histological type
TCC 39 92.9
AC 1 2.4
SCC 1 2.4
TCC & SCC 1 2.4
Grade
Low grade 27 64.3
High grade 15 35.7
Stage
Stage 1 30 71.4
Stage 2 11 26.2
Stage 3 1 2.4
*When applicable; TCC: transitional cell carcinoma; AC: adeno-
carcinoma; SCC: squamous cell carcinoma.
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staining endothelial cells over three fields in each slide.
The microvessel density (MVD) was defined as the
average value of the three readings.
Statistical analysis
SPSS for Windows (18.0.2 SPSS, Inc. Chicago, Illinois,
USA) was used for statistical analysis. Frequency tables
were analyzed using the Chi-square test, with Fisher’s
exact test (where appropriate), or likelihood ratio (LR)
statistics to assess the significance between categorical
variables. Differences in the means of continuous vari-
ables between the groups were analyzed using ANOVA
(analysis of variance) or non-parametric tests (Mann
Whitney, KruskalWallis) tests. Reported p-values are
from two-sided tests, and in all analysis p0.05 was
regarded as the limit of statistical significance.
Results
The FVIII and CD31 expression patterns in normal
bladder, low grade urothelial carcinoma, and high grade
urothelial carcinoma are illustrated in Figs. 1, 2, and 3,
respectively. The IHC staining of FVIII and CD31 was
successful in all 42 cases. The expression of these two
markers was much higher in urinary bladder carcinoma
in comparison to normal urinary bladder. The expression
pattern of FVIII was cytoplasmic and membranous,
whereas the expression of CD31 was predominantly
membranous. The expression of CD31 was slightly
stronger than that of FVIII, with mean MVD count of
80.29 and 78.53, respectively.
The expression of both FVIII and CD31 was related to
all available clinical variables including age, sex, histolo-
gical type, grade, and stage (Table 2). Interestingly, the
expression of both markers increased with tumor stage
and grade, with significant correlation to tumor stage:
p0.001 and p.002, respectively, and a highly signifi-
cant correlation with tumor grade (p0.0001 for both)
(Table 2). Despite the small number of squamous cell
carcinomas (SCC) and adenocarcinomas (AC) included
in the present series, the MVD counts were higher in
these two histological types than in classical transitional
cell carcinoma. Both SCC and AC also presented with
higher grades and stages. The MVD was not related to
age and sex of the patients.
Discussion
Over the past two decades, assessment of angiogenesis
has emerged as a potentially useful biological prognostic
and predictive factor in all solid human tumors. With the
development of highly specific endothelial markers that
can be assessed in archival specimens, several quantitative
studies have been performed on urinary bladder carcino-
mas (11, 12). The majority of published studies have
shown a positive correlation between intra-tumoral MVD
(a measure of tumor angiogenesis) and prognosis in
bladder tumors (13, 14). A minority of studies have failed
to demonstrate such an association (9, 15, 16). These
seemingly contradictory observations may be attributed
to some crucial differences in the techniques used in
sample selection in IHC staining, antibodies, vessel
counting, and statistical analysis, although a number of
biological differences may account for the discrepancy.
Papillary bladder cancer is a pathological entity with a
well-developed branching fibrovascular core. In fact, it
has been speculated that angiogenesis is the initial
pathogenic mechanism for this type of urothelial carci-
noma (6). This architectural pattern in papillary urothe-
lial carcinoma increases the difficulty of MVD
assessment; therefore, the discrimination between prior
microvessels (fibrovascular core) and new ones (neovas-
cularization) is a hard task. Based on our observation,
Fig. 1. (A) Factor VIII expression in normal bladder
(100). (B) CD31 expression in normal bladder (100).
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are associated with angiogenesis in bladder cancer more
efficiently than anti-FVIII antibody. Similar results were
observed by Bochner and others (17).
In the present series, FVIII expression was both
membranous and cytoplasmic, whereas CD31 expression
was only membranous. These observations are in agree-
ment with the staining protocol of these endothelial cells
markers and with the results observed by Santos et al.
(18). Interestingly, despite the small number of cases,
angiogenesis was higher in AC and SCC samples, which
also substantiates the recently published data (15). This
corroborates with the known fact that AC and SCC of
the urinary bladder have a higher potential for progres-
sion, and they usually present with a more advanced
stage than transitional cell carcinomas.
We observed no significant relationship between tumor
angiogenesis and the gender of the patients, in contrast to
Emad and others (19), who in their study of 154 patients,
reported that men had tumors with a higher vascularity
than did women (p0.0015). These discrepant observa-
tions might be due to differences in sample selection; they
studied Schistosoma-associated SCC only. In addition,
the number of patients may also influence the results.
Significant correlations between MVD and tumor
stage and grade were observed in the current study,
angiogenesis increasing in parallel with increasing tumor
stage and grade (Table 2). This is fully consonant with the
observations by Ozer et al. (20), who found that Grade
III Stage pT1 bladder tumors have higher angiogenic
activity and worse prognosis. Another study by Canoglu
and coworkers (21) also confirmed that MVD in bladder
Fig. 2. (A) Factor VIII expression in low-grade urothelial
carcinoma (100). (B) CD31 expression in low-grade
urothelial carcinoma (100).
Fig. 3. (A) Factor VIII expression in high-grade urothelial
carcinoma (100). (B) CD31 expression in high-grade
urothelial carcinoma (100).
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malignant potential thus substantiating the previous
observations.
In distinct contrast to our results and those of other
previous studies (13, 20, 21), however, Herrmann et al.
(15) reported that MVD count did not show any
relationship to disease-free or overall survival, and these
authors even suggested that MVD could be considered as
a favorable prognostic sign. Chabannes et al. (3) also
found that all patients with lower MVD had a shorter
survival time and, thus, confirm the consideration of
MVD as a good prognostic factor. The most likely
explanation to this discrepancy is the different markers
used by these authors because different antibodies can
give different staining patterns. Other possible reasons
might include differences in the vessels counting, and the
use of qualitative techniques for microvasculature assess-
ment that significantly affects the results. Finally, it must
be emphasized that MVD evaluation under the micro-
scope is somewhat subjective and inter-observer variation
can be substantial.
Conclusion
Taken together, even if based on a limited number of
cases, the present data implicate that angiogenesis in
urinary bladder carcinoma increases with the tumor
grade and stage and also varies between the histological
types of the tumor. Additional studies with larger cohorts
and extended follow-up are necessary to fully elucidate
the prognostic value of IHC-based MVD counting in
bladder cancer and its potential predictive role in
selecting the treatment options on more individual basis.
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